Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)
Evaluate the efficacy and safety of Dalpiciclib combined with aromatase inhibitors as a neoadjuvant therapy in Luminal B/HER2-negative breast cancer.
Luminal B/HER2-negative Breast Cancer
DRUG: Dalpiciclib combined with aromatase inhibitors
Complete cell cycle arrest（CCCA, defined as ki67≤2.7%）rate at 2 weeks of treatment, Assess ki67 level through biopsy samples of patients, 3 years
Objective response rate (ORR), the proportion of people with clinical complete response(CR) or partial response(PR), per RECIST v1.1, 3 years
Evaluate the efficacy and safety of Dalpiciclib combined with aromatase inhibitors as a neoadjuvant therapy in Luminal B/HER2-negative breast cancer.